Appropriate hemodialysis scheduling based on therapeutic drug monitoring of carboplatin in a patient with lung cancer and chronic renal failure

Hirofumi Kamata, Koichiro Asano, Kenzo Soejima, Toru Shirahata, Michie Nakatani, Hajime Inamoto, Osamu Iketani, Yasuko Yamayoshi, Yusuke Tanigawara, Akitoshi Ishizaka

Research output: Contribution to journalArticle

Abstract

A 69-year-old woman undergoing hemodialysis due to ANCA-associated nephritis and chronic renal failure developed lung adenocarcinoma and underwent radical surgery. Upon recurrence of her cancer, she received combination chemotherapy with carboplatin (CBDCA) 150 mg/m2 and docetaxel 35-70 mg/m2. Concentration of free CBDCA in serum was monitored for 6 days after drug administration. Hemodialysis was performed 1 hour after administration of CBDCA, and on day 4. Despite the lower maximum concentration, serum CBDCA levels 20-24 h after chemotherapy in this patient were 15 to 20 times higher than in subjects with normal renal function who received CBDCA at the area under the curve (AUC) of 5. She experienced moderate to severe nausea and vomiting which persisted for 12 days. During her second course of chemotherapy, hemodialysis was performed for 3 consecutive days after drug administration. The serum CBDCA levels on day 2 or later remained lower than in the first course, and the patient experienced fewer severe side effects. Based on the data from therapeutic drug monitoring of CBDCA, hemodialysis for 3 consecutive days after drug administration has been demonstrated to be useful for treatment of a patient with chronic renal failure receiving chemotherapy with CBDCA.

Original languageEnglish
Pages (from-to)1529-1532
Number of pages4
JournalJapanese Journal of Cancer and Chemotherapy
Volume36
Issue number9
Publication statusPublished - 2009 Sep

Fingerprint

Drug Monitoring
Carboplatin
Chronic Kidney Failure
Renal Dialysis
Lung Neoplasms
docetaxel
Drug Therapy
Serum
Pharmaceutical Preparations
Antineutrophil Cytoplasmic Antibodies
Nephritis
Combination Drug Therapy
Nausea
Area Under Curve
Vomiting
Kidney
Recurrence

Keywords

  • Area under the curve
  • Carboplatin
  • Chronic renal failure
  • Hemodialysis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Appropriate hemodialysis scheduling based on therapeutic drug monitoring of carboplatin in a patient with lung cancer and chronic renal failure. / Kamata, Hirofumi; Asano, Koichiro; Soejima, Kenzo; Shirahata, Toru; Nakatani, Michie; Inamoto, Hajime; Iketani, Osamu; Yamayoshi, Yasuko; Tanigawara, Yusuke; Ishizaka, Akitoshi.

In: Japanese Journal of Cancer and Chemotherapy, Vol. 36, No. 9, 09.2009, p. 1529-1532.

Research output: Contribution to journalArticle

Kamata, Hirofumi ; Asano, Koichiro ; Soejima, Kenzo ; Shirahata, Toru ; Nakatani, Michie ; Inamoto, Hajime ; Iketani, Osamu ; Yamayoshi, Yasuko ; Tanigawara, Yusuke ; Ishizaka, Akitoshi. / Appropriate hemodialysis scheduling based on therapeutic drug monitoring of carboplatin in a patient with lung cancer and chronic renal failure. In: Japanese Journal of Cancer and Chemotherapy. 2009 ; Vol. 36, No. 9. pp. 1529-1532.
@article{94670d1194c54cd6be8dd3553b060d5f,
title = "Appropriate hemodialysis scheduling based on therapeutic drug monitoring of carboplatin in a patient with lung cancer and chronic renal failure",
abstract = "A 69-year-old woman undergoing hemodialysis due to ANCA-associated nephritis and chronic renal failure developed lung adenocarcinoma and underwent radical surgery. Upon recurrence of her cancer, she received combination chemotherapy with carboplatin (CBDCA) 150 mg/m2 and docetaxel 35-70 mg/m2. Concentration of free CBDCA in serum was monitored for 6 days after drug administration. Hemodialysis was performed 1 hour after administration of CBDCA, and on day 4. Despite the lower maximum concentration, serum CBDCA levels 20-24 h after chemotherapy in this patient were 15 to 20 times higher than in subjects with normal renal function who received CBDCA at the area under the curve (AUC) of 5. She experienced moderate to severe nausea and vomiting which persisted for 12 days. During her second course of chemotherapy, hemodialysis was performed for 3 consecutive days after drug administration. The serum CBDCA levels on day 2 or later remained lower than in the first course, and the patient experienced fewer severe side effects. Based on the data from therapeutic drug monitoring of CBDCA, hemodialysis for 3 consecutive days after drug administration has been demonstrated to be useful for treatment of a patient with chronic renal failure receiving chemotherapy with CBDCA.",
keywords = "Area under the curve, Carboplatin, Chronic renal failure, Hemodialysis",
author = "Hirofumi Kamata and Koichiro Asano and Kenzo Soejima and Toru Shirahata and Michie Nakatani and Hajime Inamoto and Osamu Iketani and Yasuko Yamayoshi and Yusuke Tanigawara and Akitoshi Ishizaka",
year = "2009",
month = "9",
language = "English",
volume = "36",
pages = "1529--1532",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "9",

}

TY - JOUR

T1 - Appropriate hemodialysis scheduling based on therapeutic drug monitoring of carboplatin in a patient with lung cancer and chronic renal failure

AU - Kamata, Hirofumi

AU - Asano, Koichiro

AU - Soejima, Kenzo

AU - Shirahata, Toru

AU - Nakatani, Michie

AU - Inamoto, Hajime

AU - Iketani, Osamu

AU - Yamayoshi, Yasuko

AU - Tanigawara, Yusuke

AU - Ishizaka, Akitoshi

PY - 2009/9

Y1 - 2009/9

N2 - A 69-year-old woman undergoing hemodialysis due to ANCA-associated nephritis and chronic renal failure developed lung adenocarcinoma and underwent radical surgery. Upon recurrence of her cancer, she received combination chemotherapy with carboplatin (CBDCA) 150 mg/m2 and docetaxel 35-70 mg/m2. Concentration of free CBDCA in serum was monitored for 6 days after drug administration. Hemodialysis was performed 1 hour after administration of CBDCA, and on day 4. Despite the lower maximum concentration, serum CBDCA levels 20-24 h after chemotherapy in this patient were 15 to 20 times higher than in subjects with normal renal function who received CBDCA at the area under the curve (AUC) of 5. She experienced moderate to severe nausea and vomiting which persisted for 12 days. During her second course of chemotherapy, hemodialysis was performed for 3 consecutive days after drug administration. The serum CBDCA levels on day 2 or later remained lower than in the first course, and the patient experienced fewer severe side effects. Based on the data from therapeutic drug monitoring of CBDCA, hemodialysis for 3 consecutive days after drug administration has been demonstrated to be useful for treatment of a patient with chronic renal failure receiving chemotherapy with CBDCA.

AB - A 69-year-old woman undergoing hemodialysis due to ANCA-associated nephritis and chronic renal failure developed lung adenocarcinoma and underwent radical surgery. Upon recurrence of her cancer, she received combination chemotherapy with carboplatin (CBDCA) 150 mg/m2 and docetaxel 35-70 mg/m2. Concentration of free CBDCA in serum was monitored for 6 days after drug administration. Hemodialysis was performed 1 hour after administration of CBDCA, and on day 4. Despite the lower maximum concentration, serum CBDCA levels 20-24 h after chemotherapy in this patient were 15 to 20 times higher than in subjects with normal renal function who received CBDCA at the area under the curve (AUC) of 5. She experienced moderate to severe nausea and vomiting which persisted for 12 days. During her second course of chemotherapy, hemodialysis was performed for 3 consecutive days after drug administration. The serum CBDCA levels on day 2 or later remained lower than in the first course, and the patient experienced fewer severe side effects. Based on the data from therapeutic drug monitoring of CBDCA, hemodialysis for 3 consecutive days after drug administration has been demonstrated to be useful for treatment of a patient with chronic renal failure receiving chemotherapy with CBDCA.

KW - Area under the curve

KW - Carboplatin

KW - Chronic renal failure

KW - Hemodialysis

UR - http://www.scopus.com/inward/record.url?scp=79959847917&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959847917&partnerID=8YFLogxK

M3 - Article

VL - 36

SP - 1529

EP - 1532

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 9

ER -